Furthermore, in a series of separate studies, we have identified metabolite biomarkers of response (BoRs) that correlate with drug responsiveness for metastatic breast cancer patients treated with CDK4/6 inhibitors as well as the anti-HER2 therapy trastuzumab; and for gastrointestinal stromal tumor (GIST) patients treated with tyrosine kinase inhibitors [41,42,43]. The gene discussed is CDK4; the disease is gastrointestinal stromal tumor.